Investment Choice Between Bristol Myers Squibb and Johnson & Johnson
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 01 2026
0mins
Source: NASDAQ.COM
- Financial Performance Comparison: Bristol Myers Squibb reported nearly $48.2 billion in revenue for fiscal 2025, reflecting a slight 0.2% decrease from the previous year, with a net income of approximately $7.1 billion and a net margin of 14.6%, indicating recovery after significant business shifts; in contrast, Johnson & Johnson achieved approximately $94.2 billion in revenue, up nearly 6% year-over-year, with a net income of $26.8 billion and a net margin of 28.5%, showcasing the strong growth potential of its diversified business model.
- Debt and Liquidity Analysis: Bristol Myers Squibb has a debt-to-equity ratio of about 2.6, indicating a high reliance on borrowed funds, with a current ratio of 1.3 suggesting adequate short-term debt coverage; in comparison, Johnson & Johnson's debt-to-equity ratio is only 0.6, with a current ratio of 1.0, reflecting its financial stability and lower debt risk.
- Market Competition and Risks: Bristol Myers Squibb faces pricing pressures from the Inflation Reduction Act, particularly regarding government-negotiated prices for key drugs like Eliquis, while the loss of exclusivity for Revlimid may open the market to cheaper generics; meanwhile, Johnson & Johnson must manage significant litigation risks related to its talc-containing products, which could impact financial results.
- Investment Value Assessment: Bristol Myers Squibb currently trades at a significant discount compared to Johnson & Johnson and the broader sector, and despite facing legal liabilities and market challenges, its
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 56.700
Low
37.00
Averages
55.86
High
68.00
Current: 56.700
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dividend Investment Opportunities in Pfizer and Bristol Myers Squibb
- Pfizer's Market Performance: Pfizer became the first biopharmaceutical company to surpass $100 billion in annual sales in 2022, but has lagged behind broader equities due to declining COVID-19 product revenues and impending patent cliffs, with a potential transformation in the next five years through its rich pipeline.
- Pipeline Potential: Pfizer's oncology drug PF'4404 is currently in phase 3 trials and is expected to deliver significant clinical wins, while its weight loss pipeline is also progressing steadily; despite poor financial results, some products are expected to drive sales growth.
- Bristol Myers' Recovery: After facing patent cliffs, Bristol Myers' revenue is slowly rebounding, and while it faces more patent expirations, the approval of a new subcutaneous version of Opdivo is expected to contribute to revenue growth in the coming years.
- Collaboration and Innovation: Bristol Myers is partnering with Johnson & Johnson to develop the next-gen anticoagulant Milvexian, which has received FDA Fast Track designation, indicating strong market potential, while also working on bispecific antibodies, with significant progress expected in the coming years.
See More
Top High-Dividend Stocks in Healthcare Sector
- AbbVie's Stability: AbbVie has increased its dividend for 50 consecutive years, currently offering a 2.65% yield, with analysts projecting a 12%-13% average annual earnings growth over the next three years, showcasing its robust ability to refresh its drug portfolio and compete in the market.
- Medtronic's Growth Potential: Medtronic has raised its dividend for 49 years, with a current yield of 3.43%, and is expected to achieve 5%-6% annualized earnings growth, while its newly launched Hugo system may provide additional growth in the robotics-assisted surgery sector.
- Bristol Myers Squibb's Risks and Opportunities: Bristol Myers Squibb offers a 4.3% dividend yield but faces risks from patent expirations that could impact revenue; however, its development pipeline aims to introduce 10 new drugs in the coming years, presenting growth potential.
- Industry Outlook Analysis: The healthcare sector is projected to reach $5.7 trillion in spending by 2025, and while high-yield stocks carry risks, the stable market demand and innovation in pharmaceuticals make long-term investments appealing.
See More
Vanguard Research Bullish on U.S. Economic Outlook
- GDP Growth Forecast: Vanguard's research projects a 3% growth in U.S. GDP by 2027, which is likely to positively impact U.S. stock markets, especially with core inflation expected to drop to 2.7%, potentially boosting bond prices.
- Value Stock Investment Opportunity: The research highlights that U.S. value stocks could be a good investment choice, as these companies are positioned to benefit from AI productivity gains without incurring upfront costs for AI data centers and capital expenditures, thereby enhancing investor return potential.
- Vanguard Value Factor ETF Performance: The Vanguard U.S. Value Factor ETF (VFVA) has seen a 28.1% increase over the past year and a 12.9% gain in the first half of 2023, underscoring its significance in a diversified portfolio, particularly with holdings across financials, consumer discretionary, and healthcare sectors.
- Bond Market Outlook: The Vanguard Total Bond Market ETF (BND) has delivered an average annual return of 3.1% since its inception in 2007, despite only 0.1% over the past five years; however, if inflation and interest rates decline as projected, future bond investments could yield better returns.
See More
Vanguard Research Bullish on Value Stocks and Bonds
- Value Stock Investment Opportunity: The Vanguard U.S. Value Factor ETF has outperformed the S&P 500 index with a 28.1% annual return over the past year, and its P/E ratio of 11 indicates a significant discount compared to the S&P 500's 25, suggesting that value stocks could be a good investment choice in the coming years.
- Bond Market Outlook: Despite the Vanguard Total Bond Market ETF's average annual return of only 0.1% over the past five years, it has delivered an average annual return of 3.1% since its inception in 2007, indicating potential for long-term investment, especially as inflation and interest rates may decline.
- Diversified Portfolio: The Vanguard U.S. Value Factor ETF holds a portfolio of 649 stocks across large-cap, mid-cap, and small-cap categories, with top sector holdings including financials (23.5%) and consumer discretionary (18.5%), ensuring broad diversification and reducing sector-specific risks.
- Low Cost Advantage: The Vanguard Total Bond Market ETF features an ultra-low expense ratio of 0.03%, making it a cost-effective option in the bond ETF space, and its diversified portfolio of 11,455 bonds provides a solid yield potential, making it suitable for a long-term investor's diversified strategy.
See More
Roche's Divarasib Shows Positive Results in Late-Stage Study
- Clinical Trial Success: Roche's Divarasib demonstrated significant efficacy in the Krascendo 1 study for previously treated KRAS G12C non-small cell lung cancer patients, showing clinically meaningful improvements in progression-free and overall survival, potentially establishing a new standard of care.
- Market Competitive Edge: This study is the only global head-to-head trial comparing KRAS G12C inhibitors, with Divarasib showing superior treatment potential against Amgen's Lumakras and BMY's Krazati, which may enhance Roche's competitive position in the lung cancer market.
- FDA Breakthrough Therapy Designation: Divarasib received Breakthrough Therapy Designation from the FDA in 2022, which is expected to expedite its approval process, addressing the urgent treatment needs of patients with KRAS G12C mutations and filling a significant market gap.
- Strategic Collaboration Expansion: Roche entered into an exclusive licensing agreement with Nurix Therapeutics to co-develop and commercialize bexobrutideg, which is expected to provide new growth opportunities for Roche's hematology pipeline while strengthening its presence in immunology and neurology.
See More
Investment Choice Between Bristol Myers Squibb and Johnson & Johnson
- Financial Performance Comparison: Bristol Myers Squibb reported nearly $48.2 billion in revenue for fiscal 2025, reflecting a slight 0.2% decrease year-over-year, with a net income of approximately $7.1 billion and a net margin of 14.6%, indicating recovery from a significant loss in the previous year despite facing pricing pressures and loss of market exclusivity risks.
- Growth Potential of Johnson & Johnson: Johnson & Johnson achieved approximately $94.2 billion in revenue for fiscal 2025, marking a nearly 6% year-over-year increase, with a net income of around $26.8 billion and a net margin of 28.5%, demonstrating the effectiveness of its dual strategy in innovative medicines and MedTech in driving financial growth.
- Debt and Liquidity Analysis: Bristol Myers Squibb has a debt-to-equity ratio of 2.6, indicating high reliance on borrowed funds, while Johnson & Johnson's ratio stands at only 0.6, reflecting a more robust financial structure, with current ratios of 1.3 and 1.0 respectively, highlighting differences in short-term debt coverage capabilities.
- Legal Risks and Market Competition: Bristol Myers Squibb faces pricing pressures from the Inflation Reduction Act, while Johnson & Johnson must contend with significant litigation risks related to its talc-containing products, which could impact financial results, and is at a disadvantage in the competitive landscape against biosimilars, illustrating the distinct challenges each company faces in their market environments.
See More
Dividend Investment Opportunities in Pfizer and Bristol Myers Squibb
- Pfizer's Market Performance: Pfizer became the first biopharmaceutical company to surpass $100 billion in annual sales in 2022, but has lagged behind broader equities due to declining COVID-19 product revenues and impending patent cliffs, with a potential transformation in the next five years through its rich pipeline.
- Pipeline Potential: Pfizer's oncology drug PF'4404 is currently in phase 3 trials and is expected to deliver significant clinical wins, while its weight loss pipeline is also progressing steadily; despite poor financial results, some products are expected to drive sales growth.
- Bristol Myers' Recovery: After facing patent cliffs, Bristol Myers' revenue is slowly rebounding, and while it faces more patent expirations, the approval of a new subcutaneous version of Opdivo is expected to contribute to revenue growth in the coming years.
- Collaboration and Innovation: Bristol Myers is partnering with Johnson & Johnson to develop the next-gen anticoagulant Milvexian, which has received FDA Fast Track designation, indicating strong market potential, while also working on bispecific antibodies, with significant progress expected in the coming years.
See More
Top High-Dividend Stocks in Healthcare Sector
- AbbVie's Stability: AbbVie has increased its dividend for 50 consecutive years, currently offering a 2.65% yield, with analysts projecting a 12%-13% average annual earnings growth over the next three years, showcasing its robust ability to refresh its drug portfolio and compete in the market.
- Medtronic's Growth Potential: Medtronic has raised its dividend for 49 years, with a current yield of 3.43%, and is expected to achieve 5%-6% annualized earnings growth, while its newly launched Hugo system may provide additional growth in the robotics-assisted surgery sector.
- Bristol Myers Squibb's Risks and Opportunities: Bristol Myers Squibb offers a 4.3% dividend yield but faces risks from patent expirations that could impact revenue; however, its development pipeline aims to introduce 10 new drugs in the coming years, presenting growth potential.
- Industry Outlook Analysis: The healthcare sector is projected to reach $5.7 trillion in spending by 2025, and while high-yield stocks carry risks, the stable market demand and innovation in pharmaceuticals make long-term investments appealing.
See More
Vanguard Research Bullish on U.S. Economic Outlook
- GDP Growth Forecast: Vanguard's research projects a 3% growth in U.S. GDP by 2027, which is likely to positively impact U.S. stock markets, especially with core inflation expected to drop to 2.7%, potentially boosting bond prices.
- Value Stock Investment Opportunity: The research highlights that U.S. value stocks could be a good investment choice, as these companies are positioned to benefit from AI productivity gains without incurring upfront costs for AI data centers and capital expenditures, thereby enhancing investor return potential.
- Vanguard Value Factor ETF Performance: The Vanguard U.S. Value Factor ETF (VFVA) has seen a 28.1% increase over the past year and a 12.9% gain in the first half of 2023, underscoring its significance in a diversified portfolio, particularly with holdings across financials, consumer discretionary, and healthcare sectors.
- Bond Market Outlook: The Vanguard Total Bond Market ETF (BND) has delivered an average annual return of 3.1% since its inception in 2007, despite only 0.1% over the past five years; however, if inflation and interest rates decline as projected, future bond investments could yield better returns.
See More
Vanguard Research Bullish on Value Stocks and Bonds
- Value Stock Investment Opportunity: The Vanguard U.S. Value Factor ETF has outperformed the S&P 500 index with a 28.1% annual return over the past year, and its P/E ratio of 11 indicates a significant discount compared to the S&P 500's 25, suggesting that value stocks could be a good investment choice in the coming years.
- Bond Market Outlook: Despite the Vanguard Total Bond Market ETF's average annual return of only 0.1% over the past five years, it has delivered an average annual return of 3.1% since its inception in 2007, indicating potential for long-term investment, especially as inflation and interest rates may decline.
- Diversified Portfolio: The Vanguard U.S. Value Factor ETF holds a portfolio of 649 stocks across large-cap, mid-cap, and small-cap categories, with top sector holdings including financials (23.5%) and consumer discretionary (18.5%), ensuring broad diversification and reducing sector-specific risks.
- Low Cost Advantage: The Vanguard Total Bond Market ETF features an ultra-low expense ratio of 0.03%, making it a cost-effective option in the bond ETF space, and its diversified portfolio of 11,455 bonds provides a solid yield potential, making it suitable for a long-term investor's diversified strategy.
See More
Roche's Divarasib Shows Positive Results in Late-Stage Study
- Clinical Trial Success: Roche's Divarasib demonstrated significant efficacy in the Krascendo 1 study for previously treated KRAS G12C non-small cell lung cancer patients, showing clinically meaningful improvements in progression-free and overall survival, potentially establishing a new standard of care.
- Market Competitive Edge: This study is the only global head-to-head trial comparing KRAS G12C inhibitors, with Divarasib showing superior treatment potential against Amgen's Lumakras and BMY's Krazati, which may enhance Roche's competitive position in the lung cancer market.
- FDA Breakthrough Therapy Designation: Divarasib received Breakthrough Therapy Designation from the FDA in 2022, which is expected to expedite its approval process, addressing the urgent treatment needs of patients with KRAS G12C mutations and filling a significant market gap.
- Strategic Collaboration Expansion: Roche entered into an exclusive licensing agreement with Nurix Therapeutics to co-develop and commercialize bexobrutideg, which is expected to provide new growth opportunities for Roche's hematology pipeline while strengthening its presence in immunology and neurology.
See More
Investment Choice Between Bristol Myers Squibb and Johnson & Johnson
- Financial Performance Comparison: Bristol Myers Squibb reported nearly $48.2 billion in revenue for fiscal 2025, reflecting a slight 0.2% decrease year-over-year, with a net income of approximately $7.1 billion and a net margin of 14.6%, indicating recovery from a significant loss in the previous year despite facing pricing pressures and loss of market exclusivity risks.
- Growth Potential of Johnson & Johnson: Johnson & Johnson achieved approximately $94.2 billion in revenue for fiscal 2025, marking a nearly 6% year-over-year increase, with a net income of around $26.8 billion and a net margin of 28.5%, demonstrating the effectiveness of its dual strategy in innovative medicines and MedTech in driving financial growth.
- Debt and Liquidity Analysis: Bristol Myers Squibb has a debt-to-equity ratio of 2.6, indicating high reliance on borrowed funds, while Johnson & Johnson's ratio stands at only 0.6, reflecting a more robust financial structure, with current ratios of 1.3 and 1.0 respectively, highlighting differences in short-term debt coverage capabilities.
- Legal Risks and Market Competition: Bristol Myers Squibb faces pricing pressures from the Inflation Reduction Act, while Johnson & Johnson must contend with significant litigation risks related to its talc-containing products, which could impact financial results, and is at a disadvantage in the competitive landscape against biosimilars, illustrating the distinct challenges each company faces in their market environments.
See More
